Berlin – – September 30, 2026 -- TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an IVDR-approved in vitro diagnostic test that simultaneously screens newborns for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) in countries accepting the CE mark.

Washington – September 30, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) reported positive topline results from a pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD), setting up a supplemental New Drug Application (sNDA) filing with the U.S. Food and Drug Administration (FDA).

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its investigational triple hormone receptor agonist retatrutide produced an average weight loss of 49.6 lbs (20.8%) over 80 weeks at the 12 mg dose in patients with type 2 diabetes and obesity, with more than half of participants no longer meeting BMI criteria for obesity. The Phase 3 TRIUMPH-2 results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and simultaneously published in The Lancet.

Kista, Sweden – September 29, 2026 -- Sivers Semiconductors AB has called an Extraordinary General Meeting for 22 October 2026 to replace auditor Deloitte AB with Ernst & Young AB, a move tied to the company's plan for a dual listing on U.S. capital markets expected in the first half of 2027.

Miami – September 29, 2026 -- Jeeves, a stablecoin-native banking platform for global enterprises, has raised $110 million in equity funding and launched a proprietary stablecoin wallet with payouts to 190 countries.

Indianapolis – September 29, 2026 -- Eli Lilly and Company said a new indirect treatment comparison shows Zepbound (tirzepatide) 15 mg produced 4.5% greater body-weight loss than Novo Nordisk's Wegovy HD (semaglutide 7.2 mg) in adults with obesity, intensifying the competitive battle in the obesity-drug market. The 10 mg dose of Zepbound delivered 3.2% greater weight reduction than Wegovy HD, according to data presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan.

Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.

Uppsala – – September 29, 2026 -- Metacon AB has launched a 20 MW multi-level alkaline electrolysis module designed to cut balance-of-plant costs for large-scale hydrogen production by up to 70% on area-related infrastructure.

Zurich – September 29, 2026 -- Amcor (NYSE: AMCR, ASX: AMC) confirmed that Graeme Liebelt will step down as Chairman after nearly 13 years, with the Board electing Tom Long as his successor effective at the company's Nov. 11, 2026 annual meeting.

Berlin – September 29, 2026 -- Huawei has launched Intelligent RAIL 2.0, a portfolio of 20 scenario-based solutions targeting railway construction, passenger and freight transport, and facility maintenance, unveiled at InnoTrans 2026 held September 22-25 in Berlin.